SRZN vs. FULC, IMAB, CYRX, SLDB, OCGN, CGEM, DRUG, FDMT, NGNE, and DBVT
Should you be buying Surrozen stock or one of its competitors? The main competitors of Surrozen include Fulcrum Therapeutics (FULC), I-Mab (IMAB), CryoPort (CYRX), Solid Biosciences (SLDB), Ocugen (OCGN), Cullinan Therapeutics (CGEM), Bright Minds Biosciences (DRUG), 4D Molecular Therapeutics (FDMT), Neurogene (NGNE), and DBV Technologies (DBVT). These companies are all part of the "pharmaceutical products" industry.
Surrozen vs. Its Competitors
Fulcrum Therapeutics (NASDAQ:FULC) and Surrozen (NASDAQ:SRZN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.
89.8% of Fulcrum Therapeutics shares are held by institutional investors. Comparatively, 66.6% of Surrozen shares are held by institutional investors. 7.0% of Fulcrum Therapeutics shares are held by company insiders. Comparatively, 45.2% of Surrozen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Fulcrum Therapeutics has a beta of 2.93, suggesting that its stock price is 193% more volatile than the S&P 500. Comparatively, Surrozen has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500.
Fulcrum Therapeutics currently has a consensus price target of $11.20, indicating a potential upside of 16.28%. Surrozen has a consensus price target of $38.50, indicating a potential upside of 183.09%. Given Surrozen's higher probable upside, analysts clearly believe Surrozen is more favorable than Fulcrum Therapeutics.
In the previous week, Fulcrum Therapeutics had 8 more articles in the media than Surrozen. MarketBeat recorded 9 mentions for Fulcrum Therapeutics and 1 mentions for Surrozen. Surrozen's average media sentiment score of 1.05 beat Fulcrum Therapeutics' score of 0.44 indicating that Surrozen is being referred to more favorably in the news media.
Fulcrum Therapeutics has higher revenue and earnings than Surrozen. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.
Fulcrum Therapeutics has a net margin of 0.00% compared to Surrozen's net margin of -274.42%. Fulcrum Therapeutics' return on equity of -31.05% beat Surrozen's return on equity.
Summary
Fulcrum Therapeutics beats Surrozen on 12 of the 17 factors compared between the two stocks.
Get Surrozen News Delivered to You Automatically
Sign up to receive the latest news and ratings for SRZN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SRZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Surrozen Competitors List
Related Companies and Tools
This page (NASDAQ:SRZN) was last updated on 10/21/2025 by MarketBeat.com Staff
Free SRZN Stock Alerts